Institut Pasteur De Lille

Institut National De La Sante Et De La Recherche Medicale

Other

National University of Singapore

Nationaluniversity of Ireland, Maynooth

Smithkline Beecham Biologicals S.a.

Centre National De La Recherche Scientifique

Université Libre De Bruxelles

Aeras

Universite Droit Et Sante Lille II

Universite De Lille 2, Universite Du Droit Et De La Sante

Unstitut National De La Sante Et De La Rechereche Medicale

Universite Du Droit Et De La Sante De Lille II

Universite Du Droit Et De La Sante - Lille II

Camille Locht

Dominique Raze

Nathalie Mielcarek

Anne-Sophie Debrie

Julie Bertout

Bernard Mahon

Heather Kavanagh

Sylvie Claudette Alonso

Franco Menozzi

Alain Baulard

Rui Li

Yves Lobet

Gilles Riveau

Rui Fen Annabelle Lim

Luis Solans

Patrick Berche

Vincent Escuyer

Saliha Ait-Yahia Sendid

Anne Tsicopoulos

Nadia Haddad

Kevin Pethe

Nicolas Willand

Andre Capron

John Fulkerson

Christian Sergheraert

Vincent Villeret

Sammy Place

Juana Magdalena

Jean-Michel Hougardy

Genevieve Renauld

Kamalakannan Velmurugan

Francoise Jacob-Dubuisson

Philip Supply

Michael Brennan

Odile Poulain-Godefroy

Andr&eacute; Capron

Vincent Chow

Hana Kammoun

Heather Kavanaugh

Benoît Deprez

Bertrand Dirie

Patrick Toto

Annabelle Rui Fen Lim

Françoise Mascart

Stéphane Temmerman

Kévin Pethe

A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinicalisolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

strains expressing serotype 3 fimbriae

The present invention relates to a live attenuatedvaccine which is deficient for tracheal cytotoxin (TCT),toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

[object Object]

A mutatedstrain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutatedstrain can be used in an immunogenic composition or a vaccine for the treatment or prevention of ainfection. Use of the attenuatedstrain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection byare also provided.

Attenuatedstrains

The present invention relates to a live attenuatedvaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficientbacteria sufficient to colonize the respiratory tract of the subject. The step of infecting the subject with the live attenuated pertactin-deficientbacteria results in reduction or prevention of the development of airway inflammation in the subject.

Mutantstrains and methods of use

The present invention relates to a life attenuatedvaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

A CyaA-deficientmutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced bystrains not deficient in CyaA.

Prevention of pertussis using adenylate cyclase deficient Bordetella strains

Attenuated Bordetella strains

A CyaA-deficientmutant was constructed and used in a vaccine. The-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced bystrains not deficient in CyaA.

Recombinant(rMyc) which contain sequences encoding a heparin-binding hemagglutinin (HBHA) fusion protein are provided, as are methods of making and using the rMyc and the fusion protein. The fusion protein includes an amino terminal mycobacterial antigen Ag85B leader peptide and transcription of the fusion protein is driven by an Ag85B promoter sequence. The recombinant fusion protein is produced in abundance by the rMyc, is post-translationally methylated, and is highly antigenic.

Recombinant mycobacterium encoding a heparin-binding hemagglutinin (HBHA) fusion protein and uses thereof

Growing community of inventors

Brussels, Belgium

Camille Locht